A carregar...
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. Furthermore, AZD9291 is now being evaluated as a first-line treatment for NSCLC patients with activation EGFR mutations. Based on previous exp...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5895014/ https://ncbi.nlm.nih.gov/pubmed/29641535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0194730 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|